ECSP077220A - Tratamiento de infecciones bacterianas - Google Patents

Tratamiento de infecciones bacterianas

Info

Publication number
ECSP077220A
ECSP077220A EC2007007220A ECSP077220A ECSP077220A EC SP077220 A ECSP077220 A EC SP077220A EC 2007007220 A EC2007007220 A EC 2007007220A EC SP077220 A ECSP077220 A EC SP077220A EC SP077220 A ECSP077220 A EC SP077220A
Authority
EC
Ecuador
Prior art keywords
bacterial infection
infection treatment
treatment
relates
present
Prior art date
Application number
EC2007007220A
Other languages
English (en)
Inventor
James Peter Burnie
Ruth Christine Matthews
Tracey Carter
Original Assignee
Neutec Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Pharma Plc filed Critical Neutec Pharma Plc
Publication of ECSP077220A publication Critical patent/ECSP077220A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a compuestos, medicamentos y tratamiento para infección por Clostridium difficile, junto con anticuerpos aislados novedosos y su uso en la misma. La presente invención también se refiere a la profilaxis y tratamiento de infección por E. faecium y E. faecalis y provee medicamentos y tratamientos para las mismas.
EC2007007220A 2004-07-02 2007-02-02 Tratamiento de infecciones bacterianas ECSP077220A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0414886.2A GB0414886D0 (en) 2004-07-02 2004-07-02 Treatment of bacterial infections

Publications (1)

Publication Number Publication Date
ECSP077220A true ECSP077220A (es) 2007-03-29

Family

ID=32843487

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007220A ECSP077220A (es) 2004-07-02 2007-02-02 Tratamiento de infecciones bacterianas

Country Status (19)

Country Link
US (1) US7608265B2 (es)
EP (1) EP1763539A1 (es)
JP (1) JP2008505621A (es)
KR (1) KR20070038539A (es)
CN (1) CN101014621A (es)
AU (1) AU2005258938A1 (es)
BR (1) BRPI0512740A (es)
CA (1) CA2569557A1 (es)
EC (1) ECSP077220A (es)
GB (1) GB0414886D0 (es)
IL (1) IL180459A0 (es)
MA (1) MA28694B1 (es)
MX (1) MXPA06015081A (es)
NO (1) NO20070567L (es)
NZ (1) NZ552110A (es)
RU (1) RU2377251C2 (es)
TN (1) TNSN06453A1 (es)
WO (1) WO2006003426A1 (es)
ZA (1) ZA200610279B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013071409A1 (en) 2011-11-18 2013-05-23 National Research Council Of Canada (Nrc) Clostridium difficile lipoteichoic acid and uses thereof
WO2013112582A1 (en) 2012-01-23 2013-08-01 Santalis Pharmaceuticals Inc. Sandalwood oil and its uses related to clostridium infections
WO2014085821A2 (en) * 2012-11-30 2014-06-05 The Regents Of The University Of California Fully human antibodies and fragments recognizing human c-met
CN103044527B (zh) * 2012-12-21 2014-08-06 南昌大学 庆大霉素的抗原模拟表位及其应用
US11291693B2 (en) 2015-06-25 2022-04-05 Synlogic Operating Company, Inc. Bacteria engineered to treat metabolic diseases
KR102487338B1 (ko) * 2020-12-18 2023-01-12 한국지질자원연구원 점토광물 복합체를 포함하는 cdi 치료용 약학적 조성물 및 그 제조방법
US20250230260A1 (en) * 2022-04-15 2025-07-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cdrs for glycosylated acat1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
AU4831590A (en) 1988-12-29 1990-08-01 Cytogen Corporation Molecular recognition units
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0779819A1 (en) 1994-09-06 1997-06-25 Galagen Inc. Therapeutic treatment of clostridium difficile associated diseases
EP0750907B1 (en) * 1995-06-30 2002-03-20 American Cyanamid Company Stable macrolide and macrolide vaccine compositions
GB9621295D0 (en) 1995-12-07 1996-11-27 Cambridge Antibody Tech Specific binding members,materials and methods
DE19739685A1 (de) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
EP2305303A3 (en) 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
ATE217889T1 (de) 1998-08-28 2002-06-15 Genentech Inc Humane antikörper gegen faktor ix/ixa
WO2001027279A1 (en) * 1999-10-12 2001-04-19 Cambridge Antibody Technology Human anti-adipocyte monoclonal antibodies and their use
AU770115B2 (en) * 1999-12-13 2004-02-12 Cambridge Antibody Technology Limited Brain specific binding members
AU2001281824A1 (en) * 2000-06-15 2001-12-24 Patrizia Castellani Methods for quantitative determination of b-fibronectin in biological fluids and tissues
US7354759B2 (en) 2001-01-15 2008-04-08 Keryos Spa DNA vaccines expressing hypervariable VH-CDR3 idiotypic determinants
WO2002062379A2 (en) 2001-02-09 2002-08-15 The Provost, Fellows And Scholars Of The College Of The Holy And Unidivided Trinity Of Queen Elizabeth Clostridium difficile vaccine
ATE550352T1 (de) 2001-12-03 2012-04-15 Alexion Pharma Inc Verfahren zur herstellung von hybridantikörper
GB0130267D0 (en) * 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies

Also Published As

Publication number Publication date
MA28694B1 (fr) 2007-06-01
NZ552110A (en) 2010-11-26
NO20070567L (no) 2007-01-30
WO2006003426A1 (en) 2006-01-12
TNSN06453A1 (en) 2008-02-22
RU2377251C2 (ru) 2009-12-27
KR20070038539A (ko) 2007-04-10
US7608265B2 (en) 2009-10-27
CA2569557A1 (en) 2006-01-12
CN101014621A (zh) 2007-08-08
AU2005258938A1 (en) 2006-01-12
IL180459A0 (en) 2007-06-03
US20080038266A1 (en) 2008-02-14
JP2008505621A (ja) 2008-02-28
RU2007104033A (ru) 2008-08-10
MXPA06015081A (es) 2007-07-20
GB0414886D0 (en) 2004-08-04
ZA200610279B (en) 2008-08-27
EP1763539A1 (en) 2007-03-21
BRPI0512740A (pt) 2008-04-08

Similar Documents

Publication Publication Date Title
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
ECSP077220A (es) Tratamiento de infecciones bacterianas
BRPI0810064B8 (pt) compostos contendo nitrogênio tricíclico como agentes antibacterianos, composições farmacêuticas que compreendem os ditos compostos e uso dos mesmos para o tratamento de infecções bacterianas em mamíferos
BR112012010270A2 (pt) mentisulfonilmetano (msm) para tratamento de micro-organismos resistentes a fármaco
SG196782A1 (en) Compositions and methods for the increased production of isoprene and other products with 6 - phosphogluconolactonase (pgl)
NO20070782L (no) Tetrapeptidanaloger.
NO20074238L (no) Fiksert dosering av HER-antistoffer
BR122020006906B8 (pt) compostos e composições farmacêuticas antivirais
UY27720A1 (es) Aroilpiridinonas monocíclicas,
DOP2006000268A (es) Agentes antibacterianos
UY28313A1 (es) Nonadepsipeptidos acilados
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
ECSP045397A (es) 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS
BRPI0519710A2 (pt) aminoÁlcoois tricÍclicos, processo para sua preparaÇço e seu emprego como anti-inflamatàrio
HN2002000366A (es) Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma
BRPI0408848B8 (pt) composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação
ATE510845T1 (de) Antibakterielle makrozyklen mit substituiertem biphenyl
UY30629A1 (es) Nuevo péptido de actinomadura namibiensis
AR053775A1 (es) Nonadepsipeptidos acilados ii
CR9108A (es) Prevencion de infecciones endoparasitas verticales
ECSP045405A (es) Penems 6-alquiliden heterotriciclil como inhibidores de la beta lactamasa
ECSP066805A (es) Compuestos silinano como inhibidores de cisteína proteasa
ATE433459T1 (de) Desoxo-nonadepsipeptide
EA200870058A1 (ru) Композиции, содержащие остеопонтин крупного рогатого скота, для улучшения процесса заживления ран
ATE495186T1 (de) Antibakterielle amid-makrozyklen iv